These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 35327341)

  • 1. Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination.
    Longoria V; Parcel H; Toma B; Minhas A; Zeine R
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
    Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
    Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
    Mecha M; Feliú A; Iñigo PM; Mestre L; Carrillo-Salinas FJ; Guaza C
    Neurobiol Dis; 2013 Nov; 59():141-50. PubMed ID: 23851307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
    Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS
    Front Immunol; 2019; 10():1921. PubMed ID: 31497013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.
    Navarrete C; Carrillo-Salinas F; Palomares B; Mecha M; Jiménez-Jiménez C; Mestre L; Feliú A; Bellido ML; Fiebich BL; Appendino G; Calzado MA; Guaza C; Muñoz E
    J Neuroinflammation; 2018 Mar; 15(1):64. PubMed ID: 29495967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
    Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
    Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
    Feliú A; Moreno-Martet M; Mecha M; Carrillo-Salinas FJ; de Lago E; Fernández-Ruiz J; Guaza C
    Br J Pharmacol; 2015 Jul; 172(14):3579-95. PubMed ID: 25857324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization of progenitors in the subventricular zone to undergo oligodendrogenesis in the Theiler's virus model of multiple sclerosis: implications for remyelination at lesions sites.
    Mecha M; Feliú A; Carrillo-Salinas FJ; Mestre L; Guaza C
    Exp Neurol; 2013 Dec; 250():348-52. PubMed ID: 24148569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG; Vila C
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Reported Spinal Cord Lesions in Progressive Multiple Sclerosis with Theiler's Murine Encephalomyelitis Virus Induced Demyelinating Disease.
    Leitzen E; Jin W; Herder V; Beineke A; Elmarabet SA; Baumgärtner W; Hansmann F
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review.
    Mecha M; Carrillo-Salinas FJ; Feliú A; Mestre L; Guaza C
    Front Cell Neurosci; 2020; 14():34. PubMed ID: 32140100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
    Maniscalco GT; Aponte R; Bruzzese D; Guarcello G; Manzo V; Napolitano M; Moreggia O; Chiariello F; Florio C
    Neurol Sci; 2018 Jan; 39(1):97-102. PubMed ID: 29052091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.